Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study-Reference-Cited by-同舟云学术

Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study

Published:2023-01 Issue:1 Volume:24 Page:1-10
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Mordant Pierre,Brosseau Solenn,Milleron Bernard,Santelmo Nicola,Fraboulet-Moreau Séverine,Besse Benjamin,Langlais Alexandra,Gossot Dominique,Thomas Pascal-Alexandre,Pujol Jean-Louis,Ricordel Charles,Madelaine Jeannick,Lamy Régine,Audigier-Valette Clarisse,Missy Pascale,Blons Hélène,Barlesi Fabrice,Westeel Virginie

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations;Remon;J Thorac Oncol,2020

2. The IASLC lung cancer staging project: analysis of resection margin status and proposals for residual tumor descriptors for non-small cell lung cancer;Edwards;J Thorac Oncol,2020

3. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study;Zhong;Lancet Oncol,2018

4. Osimertinib in resected EGFR-mutated non-small-cell lung cancer;Wu;N Engl J Med,2020

5. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virtual Screening, Molecular Dynamics Simulation, and Bioactivity Assessment Validate T13074 as a Dual-Target EGFR/c-Met Inhibitor;Current Medicinal Chemistry;2024-06-24

2. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges;Journal of Thoracic Oncology;2023-09

3. Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma;Diagnostics;2023-01-20

4. Non-small-cell lung cancer with EGFR mutation in early stage;Revisiones en Cáncer;2023

5. Real-world study of disease-free survival & patient characteristics associated with disease-free survival in early-stage non-small cell lung cancer: A retrospective observational study;Cancer Treatment and Research Communications;2023